WO2010135411A3 - Aurora-a copy number and sensitivity to inhibitors - Google Patents

Aurora-a copy number and sensitivity to inhibitors Download PDF

Info

Publication number
WO2010135411A3
WO2010135411A3 PCT/US2010/035376 US2010035376W WO2010135411A3 WO 2010135411 A3 WO2010135411 A3 WO 2010135411A3 US 2010035376 W US2010035376 W US 2010035376W WO 2010135411 A3 WO2010135411 A3 WO 2010135411A3
Authority
WO
WIPO (PCT)
Prior art keywords
aai
inhibitors
sensitivity
copy number
agonist
Prior art date
Application number
PCT/US2010/035376
Other languages
French (fr)
Other versions
WO2010135411A2 (en
Inventor
Marileila Varella-Garcia
Original Assignee
The Regents Of The University Of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado filed Critical The Regents Of The University Of Colorado
Publication of WO2010135411A2 publication Critical patent/WO2010135411A2/en
Publication of WO2010135411A3 publication Critical patent/WO2010135411A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Disclosed is the identification, provision and use of biomarkers predictive of sensitivity or resistance to AAI inhibitors and products and processes related thereto. Specifically, a method is described for selecting a cancer patient predicted to benefit from therapeutic administration of an AAI inhibitor, an agonist thereof, or a drug having substantially similar biological activity as AAI inhibitor. Also described is a method to identify molecules that interact with the AAI pathway to allow or enhance responsiveness to AAI inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the copy number or expression of genes that are indicative of sensitivity or resistance to AAI inhibitors, an agonist thereof, or a drug having substantially similar biological activity as AAI inhibitors. A method to identify a compound with the potential to enhance the efficacy of AAI inhibitors is also described.
PCT/US2010/035376 2009-05-19 2010-05-19 Aurora-a copy number and sensitivity to inhibitors WO2010135411A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17961009P 2009-05-19 2009-05-19
US61/179,610 2009-05-19

Publications (2)

Publication Number Publication Date
WO2010135411A2 WO2010135411A2 (en) 2010-11-25
WO2010135411A3 true WO2010135411A3 (en) 2011-01-13

Family

ID=43126743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/035376 WO2010135411A2 (en) 2009-05-19 2010-05-19 Aurora-a copy number and sensitivity to inhibitors

Country Status (1)

Country Link
WO (1) WO2010135411A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145129A2 (en) 2011-04-18 2012-10-26 Cornell University Molecular subtyping, prognosis and treatment of prostate cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267304A1 (en) * 2001-06-21 2005-12-01 Aventis Pharmaceuticals Inc. Azaindoles
US20080182255A1 (en) * 2002-03-13 2008-07-31 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues
US20080234265A1 (en) * 2005-03-11 2008-09-25 The Regents Of The University Of Colorado Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors
US20080312223A1 (en) * 2004-12-30 2008-12-18 Astex Therapeutics Limited Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267304A1 (en) * 2001-06-21 2005-12-01 Aventis Pharmaceuticals Inc. Azaindoles
US20080182255A1 (en) * 2002-03-13 2008-07-31 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues
US20080312223A1 (en) * 2004-12-30 2008-12-18 Astex Therapeutics Limited Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
US20080234265A1 (en) * 2005-03-11 2008-09-25 The Regents Of The University Of Colorado Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAR ET AL: "Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells", CANCER RES, vol. 68, no. 21, 2008, pages 8998 - 9004, XP055019166, DOI: doi:10.1158/0008-5472.CAN-08-2658 *
PARK ET AL: "Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection", J NATL CANCER INST., vol. 100, no. 19, 2008, pages 1401 - 1411, XP009113892, DOI: doi:10.1093/jnci/djn304 *

Also Published As

Publication number Publication date
WO2010135411A2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005070020A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
Bem et al. Bacterial histidine kinases as novel antibacterial drug targets
Fernández-Montalván et al. Isoform-selective ATAD2 chemical probe with novel chemical structure and unusual mode of action
Bjerke et al. Histone H3. 3 mutations drive pediatric glioblastoma through upregulation of MYCN
Cencic et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F
Stimson et al. Biomarkers for predicting clinical responses to HDAC inhibitors
Rojo-Arreola et al. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis
WO2010030857A3 (en) Egfr inhibitor therapy responsiveness
Davidovich et al. Discovery of novel isatin-based p53 inducers
EA200900927A1 (en) METHODS FOR DETERMINING CANCER STABILITY TO INHIBITORS HISTONEDEISETHYLASE
NO20083957L (en) DNA conformation
Schoop et al. On-rate based optimization of structure–kinetic relationship–surfing the kinetic map
WO2011135459A3 (en) Methods and devices for predicting treatment efficacy
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
WO2009133294A3 (en) Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules
WO2012119113A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP2147124A4 (en) Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer
WO2012028679A3 (en) Prognostic and/or predictive biomarkers and biological applications thereof
IL218935A0 (en) Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors
Harding et al. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
WO2014047463A3 (en) Libraries of compounds having desired properties and methods for making and using them
WO2011043809A9 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
FI20105252A0 (en) METHOD, ORGANIZATION AND COMPUTER SOFTWARE PRODUCT FOR ANALYZING A BIOLOGICAL OR MEDICAL SAMPLE
Sawada et al. Synthesis and anti-migrative evaluation of moverastin derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778316

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10778316

Country of ref document: EP

Kind code of ref document: A2